| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
Senkyunolide I targets multiple pathways involved in neuroprotection and inflammation. It protects the brain from focal cerebral ischemia-reperfusion injury by upregulating p-Erk1/2 and Nrf2/HO-1 and inhibiting caspase 3. Its neuroprotective effects are related to its antioxidant and anti-apoptotic properties.
|
|---|---|
| ln Vitro |
In vitro, Senkyunolide I exhibits antioxidant and anti-apoptotic properties. It has been shown to protect neuronal cells from damage. Its anti-inflammatory effects have also been observed in cellular models.
|
| ln Vivo |
In vivo, Senkyunolide I protects rat brain against focal cerebral ischemia-reperfusion injury. It has shown promise in preclinical studies as a natural anti-inflammatory agent and neuroprotective compound. It is also an anti-migraine compound.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for Senkyunolide I are not widely detailed. Its antioxidant activity can be assessed using cell-free systems like DPPH or ABTS radical scavenging assays. Its anti-inflammatory activity can be studied by measuring its ability to inhibit inflammatory mediators.
|
| Cell Assay |
In vitro cellular assays for Senkyunolide I are performed using neuronal cell lines to assess its neuroprotective effects. Cells are pre-treated with the compound and then exposed to an oxidative stressor or ischemic conditions. Cell viability and markers of apoptosis (e.g., caspase-3 activity) are measured.
|
| Animal Protocol |
In vivo animal studies for Senkyunolide I are conducted in rat models of focal cerebral ischemia-reperfusion injury. The compound is administered, and its effects on infarct volume, neurological deficit scores, and markers of oxidative stress and apoptosis in the brain are assessed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Senkyunolide I indicate that it has higher water solubility and superior oral bioavailability compared to its most prominent analog, LIG. This makes it a promising candidate for drug development.
|
| Toxicity/Toxicokinetics |
Toxicological data for Senkyunolide I are not detailed in publicly available sources. As a natural product, it is expected to have a reasonable safety profile.
|
| References |
|
| Additional Infomation |
1(3H)-Isobenzofuranone, 3-Butyl-4,5,6,7-Tetrahydro-6,7-Dihydroxy-,(3Z,6R,7R)-rel-, has been reported in Meum athamanticum, Pseudolarix amabilis, and other organisms with relevant data. It possesses antioxidant and anti-migraine activities; isolated from Ligusticum chuanxiong; its structure is described in the first reference. See also: Angelica sinensis root oil (partial).
Senkyunolide I is a natural product from Ligusticum chuanxiong. It has neuroprotective, anti-inflammatory, analgesic, and anti-thrombotic effects. It is not an approved drug but is used as a research compound. |
| Molecular Formula |
C12H16O4
|
|---|---|
| Molecular Weight |
224.25
|
| Exact Mass |
224.104
|
| CAS # |
94596-28-8
|
| PubChem CID |
5316704
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
444.8±45.0 °C at 760 mmHg
|
| Flash Point |
175.1±22.2 °C
|
| Vapour Pressure |
0.0±2.4 mmHg at 25°C
|
| Index of Refraction |
1.571
|
| LogP |
1.04
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
16
|
| Complexity |
367
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCC/C=C\1/C2=C(C(C(CC2)O)O)C(=O)O1
|
| InChi Key |
DQNGMIQSXNGHOA-WTKPLQERSA-N
|
| InChi Code |
InChI=1S/C12H16O4/c1-2-3-4-9-7-5-6-8(13)11(14)10(7)12(15)16-9/h4,8,11,13-14H,2-3,5-6H2,1H3/b9-4-
|
| Chemical Name |
(3Z)-3-butylidene-6,7-dihydroxy-4,5,6,7-tetrahydro-2-benzofuran-1-one
|
| Synonyms |
Trans-6,7-dihydroxyligustilide; Ligustilidiol, (Z)-; Senkyunolide I
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~445.93 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (11.15 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (11.15 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (11.15 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.4593 mL | 22.2965 mL | 44.5931 mL | |
| 5 mM | 0.8919 mL | 4.4593 mL | 8.9186 mL | |
| 10 mM | 0.4459 mL | 2.2297 mL | 4.4593 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
